The GLP is committed to full transparency. Download and review our 2019 Annual Report

Cuban lung-cancer vaccine reaches United States, starting clinical trials

| | November 2, 2016
web vaccine getty
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

New York Governor Andrew Cuomo announced [Oct. 26] that the US Food and Drug Administration (FDA) has green-lighted the first clinical trial to test a Cuban drug, a lung-cancer vaccine that will be combined with an FDA-approved immunotherapy called Opdivo, in the United States.

“We’re at an early stage in the development of this vaccine, which has never before been given to US patients, so we have a lot to learn through this study,” [said] Grace Day of the Roswell Park Cancer Institute, where the early-stage trial will be conducted…“But the evidence so far is encouraging.”

That evidence includes positive trial results within Cuba as well as approval from regulatory bodies in Paraguay, Peru, Bosnia and Herzegovina, and Colombia.

“It seems to provide a very modest survival benefit,” [stated] Jack West of the Swedish Cancer Institute in Seattle…“As a rule, you don’t need to debate whether something is a breakthrough years after it has been used routinely in another part of the world.”

The GLP aggregated and excerpted this blog/article to reflect the diversity of news, opinion, and analysis. Read full, original post: FDA Approves Clinical Trials to Test Cuban Cancer Vaccine

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend